ArticleAdvances in hematology2021

A Phase II Trial of Melphalan Based Reduced-Intensity Conditioning for Transplantation of T-Replete HLA-Haploidentical Peripheral Blood Stem Cells with Posttransplant Cyclophosphamide in Patients with Hematologic Malignancies.

Melhem M Solh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.